What Hounsfield unit (HU) value is optimal for extracorporeal shock wave lithotripsy (ESWL)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Hounsfield Unit Threshold for ESWL Success

For optimal patient selection for ESWL, stones with density <750-970 HU should be considered favorable candidates, while stones ≥1000 HU have poor fragmentation rates and should be offered alternative treatments like ureteroscopy or PCNL.

Evidence-Based HU Thresholds

The research evidence consistently demonstrates an inverse relationship between stone density and ESWL success rates:

Primary Threshold: 970 HU

A prospective study of 50 patients established 970 HU as the most sensitive (100%) and specific (81%) cutoff point for predicting ESWL success 1. Stones <970 HU achieved a 96% stone-free rate compared to only 38% for stones ≥970 HU (P<0.001). This represents the single strongest evidence for clinical decision-making.

Supporting Thresholds

  • 750-1000 HU range: A systematic review of 4,206 patients found mean stone density cutoffs ranging from 750-1000 HU across multiple studies, with HU <750 consistently associated with ESWL success 2
  • >1000 HU: Strongly associated with ESWL failure across multiple studies 2
  • 857 HU: Identified as a significant predictor in subgroup analysis for proximal ureteral stones 3

Clinical Application Algorithm

Step 1: Obtain non-contrast CT and measure mean stone density

  • Use standardized CT parameters (120 kV, 100 mA)
  • Measure mean HU of the entire stone, not just peak density

Step 2: Apply HU-based treatment selection

  • <750 HU: Excellent ESWL candidate - proceed with confidence
  • 750-970 HU: Good ESWL candidate - counsel patient on favorable odds
  • 970-1000 HU: Marginal ESWL candidate - consider patient factors and stone size; URS may be preferable
  • ≥1000 HU: Poor ESWL candidate - offer URS or PCNL as first-line therapy

Additional Predictive Factors

Beyond mean HU, consider these CT texture analysis metrics that enhance prediction:

  • Stone heterogeneity index: Higher heterogeneity (cut-off 213) predicts better fragmentation, especially for larger stones 2
  • Kurtosis: High kurtosis combined with low mean HU indicates higher ESWL success 3
  • Stone size: Success rates decline with increasing burden; <10mm stones have better outcomes regardless of density 4

Guideline Context

While current AUA/EAU guidelines 4, 5 emphasize stone size, location, and composition as primary ESWL selection criteria, they acknowledge that stone density affects success rates. The guidelines note that patients selected for ESWL should have "favorable parameters" to maximize stone-free rates 4. HU measurement provides objective data to identify these favorable candidates.

Common Pitfalls to Avoid

  1. Using peak HU instead of mean HU: Mean density is more predictive than peak values 2
  2. Ignoring stone composition clues: Very high HU (>1200) suggests calcium oxalate monohydrate or cystine stones, which fragment poorly 1
  3. Proceeding with ESWL for dense stones without counseling: Patients with stones >1000 HU should be explicitly informed of low success probability and offered alternative treatments upfront
  4. Not considering combined factors: HU should be interpreted alongside stone size, location, and skin-to-stone distance for optimal prediction

Clinical Nuance

The linear relationship between stone density and ESWL success means that every 100 HU increase reduces fragmentation likelihood 1. For stones in the 750-970 HU "gray zone," additional factors become critical:

  • Stones <10mm with HU 750-970: ESWL remains reasonable
  • Stones >10mm with HU >850: Strongly favor endoscopic approaches 4, 2
  • Lower pole location with HU >750: Consider URS over ESWL 4

The 970 HU threshold provides the strongest evidence-based cutoff for counseling patients about realistic ESWL success expectations and selecting appropriate alternative treatments when indicated.

References

Related Questions

Is extracorporeal shockwave lithotripsy (ESWL) appropriate for a patient with mild left hydronephrosis and proximal hydroureter caused by a 6 mm × 5 mm obstructive stone in the proximal ureter with high attenuation (~977 HU) and mild perinephric and peri‑ureteric fat stranding?
Can I use a non-contrast computed tomography (CT) of the abdomen and pelvis to evaluate for kidney stones and pancreatitis?
What is the treatment of choice for a 0.7 cm non-obstructing stone in the right renal lower caliceal with no hydronephrosis and a density of approximately 700 Hounsfield Units (HU)?
Can a 1 mg benztropine mesylate oral tablet be split?
In an athlete with an acute grade II or III muscle tear who has not improved after 2–3 weeks of rest, compression, NSAIDs, and progressive loading, and who has no contraindications such as infection, anticoagulation, platelet disorder, or severe systemic illness, what is the role of platelet‑rich plasma (PRP) in management?
If a renal stone is not visualized on plain X‑ray, should we proceed directly with extracorporeal shock wave lithotripsy (ESWL) or first perform an ultrasound examination?
Does quetiapine cause QT interval prolongation or tachycardia?
Can the CAPOX regimen be given using a peripheral intravenous line, or is a central venous access device (port) required?
After stopping Latuda (lurasidone) 17 days ago, when will I be able to nap again?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.